These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 1915674)

  • 1. Effects of long-term administration of HMG-CoA reductase inhibitors on cholesterol synthesis in lens.
    Kalinowski SS; Tanaka RD; Mosley ST
    Exp Eye Res; 1991 Aug; 53(2):179-86. PubMed ID: 1915674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens.
    Mosley ST; Kalinowski SS; Schafer BL; Tanaka RD
    J Lipid Res; 1989 Sep; 30(9):1411-20. PubMed ID: 2513368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholesterol content of the rat lens is lowered by administration of simvastatin, but not by pravastatin.
    De Vries AC; Vermeer MA; Bredman JJ; Bär PR; Cohen LH
    Exp Eye Res; 1993 Apr; 56(4):393-9. PubMed ID: 8500554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors.
    Parker RA; Clark RW; Sit SY; Lanier TL; Grosso RA; Wright JJ
    J Lipid Res; 1990 Jul; 31(7):1271-82. PubMed ID: 2401858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
    Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M
    Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
    Koga T; Shimada Y; Kuroda M; Tsujita Y; Hasegawa K; Yamazaki M
    Biochim Biophys Acta; 1990 Jul; 1045(2):115-20. PubMed ID: 2116173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes.
    Masters BA; Palmoski MJ; Flint OP; Gregg RE; Wang-Iverson D; Durham SK
    Toxicol Appl Pharmacol; 1995 Mar; 131(1):163-74. PubMed ID: 7878672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
    Joles J; Willekes-Koolschijn N; Koomans H; Van Tol A; Geelhoed-Mieras T; Crommelin D; Van Bloois L; Krajnc-Franken M; Cohen L; Griffioen M
    Lab Anim; 1992 Oct; 26(4):269-80. PubMed ID: 1447905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue-selective inhibition of sterol synthesis in mice by pravastatin sodium after a single or repeated oral administrations.
    Koga T; Kikuchi T; Miyazaki A; Koike H
    Lipids; 1995 Aug; 30(8):775-9. PubMed ID: 7475995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
    Aoki T; Nishimura H; Nakagawa S; Kojima J; Suzuki H; Tamaki T; Wada Y; Yokoo N; Sato F; Kimata H; Kitahara M; Toyoda K; Sakashita M; Saito Y
    Arzneimittelforschung; 1997 Aug; 47(8):904-9. PubMed ID: 9296275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis.
    Alberts AW
    Cardiology; 1990; 77 Suppl 4():14-21. PubMed ID: 2073667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RG 12561 (dalvastatin): a novel synthetic inhibitor of HMG-CoA reductase and cholesterol-lowering agent.
    Amin D; Gustafson SK; Weinacht JM; Cornell SA; Neuenschwander K; Kosmider B; Scotese AC; Regan JR; Perrone MH
    Pharmacology; 1993; 46(1):13-22. PubMed ID: 8434028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of cholesterol synthesis and hepatic 3-hydroxy-3-methylglutaryl--CoA reductase in rats by simvastatin and pravastatin.
    Del Puppo M; Rauli S; Galli Kienle M
    Lipids; 1995 Nov; 30(11):1057-61. PubMed ID: 8569435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro.
    Kurakata S; Kada M; Shimada Y; Komai T; Nomoto K
    Immunopharmacology; 1996 Aug; 34(1):51-61. PubMed ID: 8880225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pravastatin and simvastatin differently inhibit cholesterol biosynthesis in human lens.
    de Vries AC; Vermeer MA; Bloemendal H; Cohen LH
    Invest Ophthalmol Vis Sci; 1993 Feb; 34(2):377-84. PubMed ID: 8440592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes.
    Qin W; Infante J; Wang SR; Infante R
    Biochim Biophys Acta; 1992 Jul; 1127(1):57-66. PubMed ID: 1627634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of propionic acid and pravastatin on HMG-CoA reductase activity in relation to forestomach lesions in the rat.
    Bueld JE; Bannenberg G; Netter KJ
    Pharmacol Toxicol; 1996 Apr; 78(4):229-34. PubMed ID: 8861780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors.
    Bocan TM; Ferguson E; McNally W; Uhlendorf PD; Bak Mueller S; Dehart P; Sliskovic DR; Roth BD; Krause BR; Newton RS
    Biochim Biophys Acta; 1992 Jan; 1123(2):133-44. PubMed ID: 1739744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.